Which medications are used in the treatment of non–small cell lung cancer (NSCLC) in patients who do not demonstrate EGFR or ALK but have high PDL-1 expression?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

In patients with NSCLC that does not demonstrate EGFR or ALK but has high PDL-1 expression, the immune checkpoint inhibitors pembrolizumab (Keytruda) and atezolizumab (Tecentriq) are approved for use as first-line therapy. They are also used in combination with chemotherapy or as a single agent in second-line and third-line therapy.

The immune checkpoint inhibitor nivolumab (Opdivo) is used in combination with ipilimumab for first-line treatment, and as monotherapy in patients with progression of metastatic NSCLC on or after platinum-based chemotherapy

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!